Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 3 results

ea0090ep721 | Pituitary and Neuroendocrinology | ECE2023

An international, simulated-use study assessing nurses’ preferences between two lanreotide syringes (Somatuline Autogel vs Pharmathen) for treatment of neuroendocrine tumours (NETs) and/or acromegaly: PRESTO 3

Ferone Diego , Martin Wendy , Williams Jessica , Houchard Aude , Pommie Christelle , Ribeiro-Oliveira Antonio , Grossman Ashley B

Introduction/Background: Patients with NETs and acromegaly are commonly treated with somatostatin analogues (SSAs), such as octreotide and lanreotide depot formulations. The Pharmathen syringe is now available in several European countries and the USA for lanreotide depot injection. When using SSAs, confidence in and ease of use with syringes is important for decision-making in long-term therapy.Aims: PRESTO 3 compared nurses’ preference for the Som...
4 shares

ea0098o6 | Other | NANETS2023

PRESTO 3: An international, simulated-use study assessing preferences of nurses between two lanreotide syringes (Somatuline® Autogel® vs Pharmathen)

Ferone Diego , Martin Wendy , Williams Jessica , Houchard Aude , Pommie Christelle , Mai Truong-Thanh Xuan , Ribeiro-Oliveira Jr. Antonio , Grossman Ashley

Background: Patients with neuroendocrine tumours (NETs) and acromegaly are commonly treated with somatostatin analogs (SSAs), such as octreotide and lanreotide depot formulations. The Pharmathen syringe is now available in several European countries and the USA for lanreotide depot injection. When using SSAs, confidence in and ease of use with syringes are important for decision-making in long-term therapy. The aim of the PRESTO 3 study was to compare nurses’ preference f...
0 shares

ea0089c1 | Clinical – Chemo/SSA/Biologics | NANETS2022

Progression-Free Survival in Patients with Bronchopulmonary Neuroendocrine Tumors Treated with Lanreotide or Placebo: Adjustment for Crossover Effects in Placebo Arm

Singh Simron , Buikhuisen Wieneke , Capdevila Jaume , Caplin Martyn E , Grohe Christian , Horsch Dieter , Raderer Markus , Reidy-Lagunes Diane , Wolin Edward M , Pommie Christelle , Mai Truong Xuan , Baudin Eric

Background: SPINET was a phase 3 trial (NCT02683941) in patients with well-differentiated, advanced bronchopulmonary neuroendocrine tumors (NETs; typical and atypical carcinoids [TCs and ACs]). During the double-blind (DB) period, patients were randomized (2:1) to receive lanreotide autogel/depot (LAN; 120 mg) or placebo (PBO) every 28 days; in the optional open-label (OL) phase, all patients received LAN. Recruitment was stopped early due to slow accrual; all eligible patient...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more